The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?

To align diversity plans to FDA's draft diversity guidance will require sponsors to shift from trial-level considerations to disease-level planning and partnership strategies. In this virtual roundtable Xoli Belgrave, Senior Director, Patient Innovation Center, is joined by other CRO, site and pharma SMEs to discuss the need for early engagement with sponsors and research partners as well as site-level strategies to reach underrepresented patient populations.

Return to Insights Center

Related Insights

Article

Bringing clinical trials to patients with the decentralized model

Jan 8, 2021

Article

Australia: Infrastructure and Innovations for Clinical Trials

Aug 28, 2023

Podcast

Decentrally Speaking | Episode 3: Integrating the Patient Voice into Decentralized Trials

Jul 28, 2022

Blog

Including patients in DCT design

Sep 13, 2022

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

A patient-centric approach to managing clinical trial complexity

Jul 13, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

Decentralized Trials: Considerations for Building a New Patient-Centric Model

May 13, 2021

Article

Decentralized clinical trials - A more patient-centric approach

May 10, 2021

Report

New Medicines, Novel Insights: Achieving patient-guided drug development

Oct 30, 2023

Blog

Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data

Oct 15, 2021